Citigroup Maintains Neutral on Pfizer, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Andrew Baum has maintained a Neutral rating on Pfizer (NYSE:PFE) and lowered the price target from $42 to $35.
October 16, 2023 | 3:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has maintained a Neutral rating on Pfizer and lowered the price target from $42 to $35.
The lowering of the price target by Citigroup indicates a potential decrease in Pfizer's stock value in the short term. This is likely to negatively impact the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100